Abstract
Purpose :
To assess the efficacy of intravitreal conbercept injections in patients with macular edema secondary to retinal vein occlusion (RVO)
Methods :
A retrospective study was performed on 30 patients with macular edema secondary to RVO, including 16 branch RVO (CRVO) and 14 central RVO (CRVO). Each patient received intravitreal injections of conbercept monthly up to 3 months, followed by monthly injection up to the evaluation of fundus until month 9.
Results :
Among 30 RVO patients (mean age: 57.13±10.40 years) in this study, 16 were BRVO and 14 were CRVO. 12 patients were males (40.00%) and 18 were females (60.00%). There was no significant difference in age (P=0.083), gender (P=0.765) study eye (P=0.301), mean duration (P=0.232), baseline BCVA (P=0.051) and IOP (P=0.237) between BRVO group and CRVO group. There were greater CMT (P=0.026) and MMT (P=0.035) in CRVO than BRVO group. At month 9, the mean change of BCVA in the BRVO and CRVO group was 25.38±8.23 and 21.29±18.29 ETDRS letters(P=0.481) and the mean change of CMT were -340.13±20.43 and -467.86±149.30um (P=0.122). There was great correlation between the change of BCVA from baseline to the last visits in all 30 patients with age (P=0.001), eye laterality (P=0.013), duration of diagnosis (P=0.018), baseline BCVA (P=0.026), baseline CMT (P=0.005), baseline MMT (P=0.048).
Conclusions :
Intravitreal injections of conbercept demonstrated a generally favorable safety and tolerability profile as well as efficacy in the treatment of macular edema due to RVO
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.